InMed Pharmaceuticals EBIT

The latest EBIT for INM is $-1.4B as of June 2026. That compares with $-14B in the prior-year period — up 89.6% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside InMed Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, INM's EBIT moved from $-14B to $-1.4B — a 89.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InMed Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, INM currently prints $-1.4B for EBIT, while the sector average sits near $22B. That is roughly 106.3% below the sector mean. Large gaps often invite a closer look at InMed Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-1.4B for INM is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting INM's EBIT ($-1.4B), review year-over-year change from $-14B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.